{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:42:14Z","timestamp":1790743334174,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH NIMH","award":["P30 MH062261"],"award-info":[{"award-number":["P30 MH062261"]}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"crossref","award":["R01-AI124965"],"award-info":[{"award-number":["R01-AI124965"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"crossref","award":["1K23AI134307-01A1"],"award-info":[{"award-number":["1K23AI134307-01A1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current strategies to treat tuberculosis (TB) and co-morbidities involve multidrug combination therapies. Rifamycin antibiotics are a key component of TB therapy and a common source of drug\u2013drug interactions (DDIs) due to induction of drug metabolizing enzymes (DMEs). Management of rifamycin DDIs are complex, particularly in patients with co-morbidities, and differences in DDI potential between rifamycin antibiotics are not well established. DME profiles induced in response to tuberculosis antibiotics (rifampin, rifabutin and rifapentine) were compared in primary human hepatocytes. We identified rifamycin induced DMEs, cytochrome P450 (<jats:italic>CYP<\/jats:italic>) <jats:italic>2C8<\/jats:italic>\/<jats:italic>3A4<\/jats:italic>\/<jats:italic>3A5<\/jats:italic>, <jats:italic>SULT2A,<\/jats:italic> and <jats:italic>UGT1A4<\/jats:italic>\/<jats:italic>1A5<\/jats:italic> and predicted lower DDIs of rifapentine with 58 clinical drugs used to treat co-morbidities in TB patients. Transcriptional networks and upstream regulator analyses showed <jats:italic>FOXA3<\/jats:italic>, <jats:italic>HNF4\u03b1<\/jats:italic>, <jats:italic>NR1I2<\/jats:italic>, <jats:italic>NR1I3<\/jats:italic>, <jats:italic>NR3C1<\/jats:italic> and <jats:italic>RXR\u03b1<\/jats:italic> as key transcriptional regulators of rifamycin induced DMEs. Our study findings are an important resource to design effective medication regimens to treat common co-conditions in TB patients.<\/jats:p>","DOI":"10.1038\/s41598-020-69228-z","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T10:04:50Z","timestamp":1595930690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics"],"prefix":"10.1038","volume":"10","author":[{"given":"Shetty Ravi","family":"Dyavar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Mykris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee C.","family":"Winchester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly K.","family":"Scarsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney V.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Podany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"69228_CR1","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.tim.2018.02.012","volume":"26","author":"A Koch","year":"2018","unstructured":"Koch, A. & Mizrahi, V. Mycobacterium tuberculosis. Trends Microbiol. 26, 555\u2013556. https:\/\/doi.org\/10.1016\/j.tim.2018.02.012 (2018).","journal-title":"Trends Microbiol."},{"key":"69228_CR2","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","volume":"18","author":"S Tiberi","year":"2018","unstructured":"Tiberi, S. et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect. Dis. 18, e183\u2013e198. https:\/\/doi.org\/10.1016\/S1473-3099(18)30110-5 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"69228_CR3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/S1470-2045(11)70105-X","volume":"12","author":"S Vento","year":"2011","unstructured":"Vento, S. & Lanzafame, M. Tuberculosis and cancer: a complex and dangerous liaison. Lancet Oncol. 12, 520\u2013522. https:\/\/doi.org\/10.1016\/S1470-2045(11)70105-X (2011).","journal-title":"Lancet Oncol."},{"key":"69228_CR4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/tmi.12026","volume":"18","author":"L Fenner","year":"2013","unstructured":"Fenner, L. et al. Tuberculosis and the risk of opportunistic infections and cancers in HIV-infected patients starting ART in Southern Africa. Trop. Med. Int. Health 18, 194\u2013198. https:\/\/doi.org\/10.1111\/tmi.12026 (2013).","journal-title":"Trop. Med. Int. Health"},{"key":"69228_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12257","volume":"264","author":"K Ronacher","year":"2015","unstructured":"Ronacher, K. et al. Acquired immunodeficiencies and tuberculosis: focus on HIV\/AIDS and diabetes mellitus. Immunol. Rev. 264, 121\u2013137. https:\/\/doi.org\/10.1111\/imr.12257 (2015).","journal-title":"Immunol. Rev."},{"key":"69228_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/QCO.0000000000000158","volume":"28","author":"I Sauzullo","year":"2015","unstructured":"Sauzullo, I., Vullo, V. & Mastroianni, C. M. Detecting latent tuberculosis in compromised patients. Curr. Opin. Infect. Dis. 28, 275\u2013282. https:\/\/doi.org\/10.1097\/QCO.0000000000000158 (2015).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"69228_CR7","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop, K. L. et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann. Rheum. Dis. 75, 1133\u20131138. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207319 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"69228_CR8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.rmcr.2017.11.004","volume":"23","author":"B Cakar","year":"2018","unstructured":"Cakar, B. & Ciledag, A. Evaluation of coexistence of cancer and active tuberculosis; 16 case series. Respir. Med. Case Rep. 23, 33\u201337. https:\/\/doi.org\/10.1016\/j.rmcr.2017.11.004 (2018).","journal-title":"Respir. Med. Case Rep."},{"key":"69228_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/COH.0000000000000506","volume":"13","author":"AC Pettit","year":"2018","unstructured":"Pettit, A. C., Shepherd, B. E. & Sterling, T. R. Treatment of drug-susceptible tuberculosis among people living with human immunodeficiency virus infection: an update. Curr. Opin. HIV AIDS 13, 469\u2013477. https:\/\/doi.org\/10.1097\/COH.0000000000000506 (2018).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"69228_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40262-014-0144-3","volume":"53","author":"M Regazzi","year":"2014","unstructured":"Regazzi, M., Carvalho, A. C., Villani, P. & Matteelli, A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. Clin. Pharmacokinet 53, 489\u2013507. https:\/\/doi.org\/10.1007\/s40262-014-0144-3 (2014).","journal-title":"Clin. Pharmacokinet"},{"key":"69228_CR11","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.2147\/DDDT.S146506","volume":"11","author":"C Zheng","year":"2017","unstructured":"Zheng, C., Hu, X., Zhao, L., Hu, M. & Gao, F. Clinical and pharmacological hallmarks of rifapentine\u2019s use in diabetes patients with active and latent tuberculosis: Do we know enough?. Drug Des. Dev. Ther 11, 2957\u20132968. https:\/\/doi.org\/10.2147\/DDDT.S146506 (2017).","journal-title":"Drug Des. Dev. Ther"},{"key":"69228_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/s0928-0987(01)00135-x","volume":"13","author":"EL LeCluyse","year":"2001","unstructured":"LeCluyse, E. L. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur. J. Pharm. Sci. 13, 343\u2013368. https:\/\/doi.org\/10.1016\/s0928-0987(01)00135-x (2001).","journal-title":"Eur. J. Pharm. Sci."},{"key":"69228_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/wsbm.1302","volume":"7","author":"RM Turner","year":"2015","unstructured":"Turner, R. M., Park, B. K. & Pirmohamed, M. Parsing interindividual drug variability: an emerging role for systems pharmacology. Wiley Interdiscip. Rev. Syst. Biol. Med. 7, 221\u2013241. https:\/\/doi.org\/10.1002\/wsbm.1302 (2015).","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"69228_CR14","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1124\/dmd.116.074732","volume":"45","author":"B Achour","year":"2017","unstructured":"Achour, B., Al Feteisi, H., Lanucara, F., Rostami-Hodjegan, A. & Barber, J. Global proteomic analysis of human liver microsomes: rapid characterization and quantification of hepatic drug-metabolizing enzymes. Drug Metab. Dispos. 45, 666\u2013675. https:\/\/doi.org\/10.1124\/dmd.116.074732 (2017).","journal-title":"Drug Metab. Dispos."},{"key":"69228_CR15","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1080\/17425255.2017.1292251","volume":"13","author":"P Mallick","year":"2017","unstructured":"Mallick, P., Taneja, G., Moorthy, B. & Ghose, R. Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions. Expert Opin. Drug Metab. Toxicol. 13, 605\u2013616. https:\/\/doi.org\/10.1080\/17425255.2017.1292251 (2017).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"69228_CR16","doi-asserted-by":"publisher","first-page":"e00386","DOI":"10.1002\/prp2.386","volume":"6","author":"BT Gufford","year":"2018","unstructured":"Gufford, B. T. et al. Rifampin modulation of xeno- and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes. Pharmacol. Res. Perspect. 6, e00386. https:\/\/doi.org\/10.1002\/prp2.386 (2018).","journal-title":"Pharmacol. Res. Perspect."},{"key":"69228_CR17","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1124\/dmd.111.040824","volume":"39","author":"IE Templeton","year":"2011","unstructured":"Templeton, I. E., Houston, J. B. & Galetin, A. Predictive utility of in vitro rifampin induction data generated in fresh and cryopreserved human hepatocytes, Fa2N-4, and HepaRG cells. Drug Metab. Dispos. 39, 1921\u20131929. https:\/\/doi.org\/10.1124\/dmd.111.040824 (2011).","journal-title":"Drug Metab. Dispos."},{"key":"69228_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1164\/ajrccm.153.1.8542137","volume":"153","author":"MM Park","year":"1996","unstructured":"Park, M. M., Davis, A. L., Schluger, N. W., Cohen, H. & Rom, W. N. Outcome of MDR-TB patients, 1983\u20131993. Prolonged survival with appropriate therapy. Am. J. Respir. Crit. Care Med. 153, 317\u2013324. https:\/\/doi.org\/10.1164\/ajrccm.153.1.8542137 (1996).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"69228_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger, U. M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103\u2013141. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.12.007 (2013).","journal-title":"Pharmacol. Ther."},{"key":"69228_CR20","first-page":"673","volume":"274","author":"AP Li","year":"1995","unstructured":"Li, A. P., Rasmussen, A., Xu, L. & Kaminski, D. L. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. J. Pharmacol. Exp. Ther. 274, 673\u2013677 (1995).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"69228_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0009-2797(97)00071-9","volume":"107","author":"AP Li","year":"1997","unstructured":"Li, A. P. et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem. Biol. Interact. 107, 17\u201330 (1997).","journal-title":"Chem. Biol. Interact."},{"key":"69228_CR22","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/S0140-6736(00)02876-2","volume":"356","author":"EF Bowen","year":"2000","unstructured":"Bowen, E. F., Rice, P. S., Cooke, N. T., Whitfield, R. J. & Rayner, C. F. HIV seroprevalence by anonymous testing in patients with Mycobacterium tuberculosis and in tuberculosis contacts. Lancet 356, 1488\u20131489. https:\/\/doi.org\/10.1016\/S0140-6736(00)02876-2 (2000).","journal-title":"Lancet"},{"key":"69228_CR23","doi-asserted-by":"publisher","first-page":"6366","DOI":"10.1128\/AAC.01124-13","volume":"57","author":"B Williamson","year":"2013","unstructured":"Williamson, B., Dooley, K. E., Zhang, Y., Back, D. J. & Owen, A. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob. Agents Chemother. 57, 6366\u20136369. https:\/\/doi.org\/10.1128\/AAC.01124-13 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69228_CR24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40262-014-0144-3","volume":"53","author":"M Regazzi","year":"2014","unstructured":"Regazzi, M., Carvalho, A. C., Villani, P. & Matteelli, A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. Clin. Pharmacokinet. 53, 489\u2013507. https:\/\/doi.org\/10.1007\/s40262-014-0144-3 (2014).","journal-title":"Clin. Pharmacokinet."},{"key":"69228_CR25","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1261\/rna.1947110","volume":"16","author":"A Git","year":"2010","unstructured":"Git, A. et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 16, 991\u20131006. https:\/\/doi.org\/10.1261\/rna.1947110 (2010).","journal-title":"RNA"},{"key":"69228_CR26","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1164\/ajrccm\/141.3.626","volume":"141","author":"LB Heifets","year":"1990","unstructured":"Heifets, L. B., Lindholm-Levy, P. J. & Flory, M. A. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 141, 626\u2013630. https:\/\/doi.org\/10.1164\/ajrccm\/141.3.626 (1990).","journal-title":"Am. Rev. Respir. Dis."},{"key":"69228_CR27","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1128\/aac.39.9.2073","volume":"39","author":"N Mor","year":"1995","unstructured":"Mor, N., Simon, B., Mezo, N. & Heifets, L. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob. Agents Chemother. 39, 2073\u20132077. https:\/\/doi.org\/10.1128\/aac.39.9.2073 (1995).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69228_CR28","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","volume":"380","author":"S Swindells","year":"2019","unstructured":"Swindells, S. et al. One Month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N. Engl. J. Med. 380, 1001\u20131011. https:\/\/doi.org\/10.1056\/NEJMoa1806808 (2019).","journal-title":"N. Engl. J. Med."},{"key":"69228_CR29","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling, T. R. et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N. Engl. J. Med. 365, 2155\u20132166. https:\/\/doi.org\/10.1056\/NEJMoa1104875 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"69228_CR30","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/clinids\/22.Supplement_1.S3","volume":"22","author":"CM Kunin","year":"1996","unstructured":"Kunin, C. M. Antimicrobial activity of rifabutin. Clin. Infect. Dis. 22(Suppl 1), S3\u2013S13 (1996) (discussion S13\u2013S14).","journal-title":"Clin. Infect. Dis."},{"key":"69228_CR31","doi-asserted-by":"publisher","first-page":"455P","DOI":"10.1111\/j.1365-2125.1978.tb04626.x","volume":"6","author":"AT Birmingham","year":"1978","unstructured":"Birmingham, A. T. et al. Antibacterial activity in serum and urine following oral administration in man of DL473 (a cyclopentyl derivative of rifampicin) [proceedings]. Br. J. Clin. Pharmacol. 6, 455P-456P. https:\/\/doi.org\/10.1111\/j.1365-2125.1978.tb04626.x (1978).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"69228_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","volume":"40","author":"WJ Burman","year":"2001","unstructured":"Burman, W. J., Gallicano, K. & Peloquin, C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40, 327\u2013341. https:\/\/doi.org\/10.2165\/00003088-200140050-00002 (2001).","journal-title":"Clin. Pharmacokinet."},{"key":"69228_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00641-18","author":"WA Alghamdi","year":"2018","unstructured":"Alghamdi, W. A., Al-Shaer, M. H. & Peloquin, C. A. Protein binding of first-line antituberculosis drugs. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00641-18 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69228_CR34","unstructured":"Food and drug administration (FDA) database weblink 1: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050689s016lbl.pdf"},{"key":"69228_CR35","unstructured":"Food and drug administration (FDA) database weblink 2: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021024s009lbl.pdf"},{"key":"69228_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0300-483X(95)03155-9","volume":"104","author":"AP Li","year":"1995","unstructured":"Li, A. P., Kaminski, D. L. & Rasmussen, A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 104, 1\u20138 (1995).","journal-title":"Toxicology"},{"key":"69228_CR37","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/infdis\/jis460","volume":"207","author":"KE Dooley","year":"2013","unstructured":"Dooley, K. E. et al. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: Unclear efficacy or untapped potential?. J. Infect. Dis. 207, 1352\u20131358. https:\/\/doi.org\/10.1093\/infdis\/jis460 (2013).","journal-title":"J. Infect. Dis."},{"key":"69228_CR38","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/03602530902843483","volume":"41","author":"SF Zhou","year":"2009","unstructured":"Zhou, S. F., Liu, J. P. & Chowbay, B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab. Rev. 41, 89\u2013295. https:\/\/doi.org\/10.1080\/03602530902843483 (2009).","journal-title":"Drug Metab. Rev."},{"key":"69228_CR39","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/jcph.507","volume":"55","author":"BW Ogilvie","year":"2015","unstructured":"Ogilvie, B. W., Torres, R., Dressman, M. A., Kramer, W. G. & Baroldi, P. Clinical assessment of drug\u2013drug interactions of tasimelteon, a novel dual melatonin receptor agonist. J. Clin. Pharmacol. 55, 1004\u20131011. https:\/\/doi.org\/10.1002\/jcph.507 (2015).","journal-title":"J. Clin. Pharmacol."},{"key":"69228_CR40","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1124\/dmd.110.035246","volume":"39","author":"JY Chung","year":"2011","unstructured":"Chung, J. Y. et al. Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Drug Metab. Dispos. 39, 92\u201397. https:\/\/doi.org\/10.1124\/dmd.110.035246 (2011).","journal-title":"Drug Metab. Dispos."},{"key":"69228_CR41","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/jac\/dkt483","volume":"69","author":"M Weiner","year":"2014","unstructured":"Weiner, M. et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J. Antimicrob. Chemother. 69, 1079\u20131085. https:\/\/doi.org\/10.1093\/jac\/dkt483 (2014).","journal-title":"J. Antimicrob. Chemother."},{"key":"69228_CR42","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1128\/AAC.01468-08","volume":"53","author":"LA Wenning","year":"2009","unstructured":"Wenning, L. A. et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob. Agents Chemother. 53, 2852\u20132856. https:\/\/doi.org\/10.1128\/AAC.01468-08 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69228_CR43","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1177\/0091270010375959","volume":"51","author":"DM Brainard","year":"2011","unstructured":"Brainard, D. M. et al. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro\/in vivo correlation. J. Clin. Pharmacol. 51, 943\u2013950. https:\/\/doi.org\/10.1177\/0091270010375959 (2011).","journal-title":"J. Clin. Pharmacol."},{"key":"69228_CR44","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/QCO.0000000000000629","volume":"33","author":"YEG Jung","year":"2020","unstructured":"Jung, Y. E. G. & Schluger, N. W. Advances in the diagnosis and treatment of latent tuberculosis infection. Curr. Opin. Infect. Dis. 33, 166\u2013172. https:\/\/doi.org\/10.1097\/QCO.0000000000000629 (2020).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"69228_CR45","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/cid\/civ464","volume":"61","author":"AT Podany","year":"2015","unstructured":"Podany, A. T. et al. Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin. Infect. Dis. 61, 1322\u20131327. https:\/\/doi.org\/10.1093\/cid\/civ464 (2015).","journal-title":"Clin. Infect. Dis."},{"key":"69228_CR46","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jpba.2014.11.011","volume":"104","author":"LC Winchester","year":"2015","unstructured":"Winchester, L. C., Podany, A. T., Baldwin, J. S., Robbins, B. L. & Fletcher, C. V. Determination of the rifamycin antibiotics rifabutin, rifampin, rifapentine and their major metabolites in human plasma via simultaneous extraction coupled with LC\/MS\/MS. J. Pharm. Biomed. Anal. 104, 55\u201361. https:\/\/doi.org\/10.1016\/j.jpba.2014.11.011 (2015).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"69228_CR47","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1038\/s41598-018-21882-0","volume":"8","author":"SR Dyavar","year":"2018","unstructured":"Dyavar, S. R. et al. Normalization of cell associated antiretroviral drug concentrations with a novel RPP30 droplet digital PCR assay. Sci. Rep. 8, 3626. https:\/\/doi.org\/10.1038\/s41598-018-21882-0 (2018).","journal-title":"Sci. Rep."},{"key":"69228_CR48","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1093\/jac\/dkz273","volume":"74","author":"SR Dyavar","year":"2019","unstructured":"Dyavar, S. R. et al. Assessing the lymphoid tissue bioavailability of antiretrovirals in human primary lymphoid endothelial cells and in mice. J. Antimicrob. Chemother. 74, 2974\u20132978. https:\/\/doi.org\/10.1093\/jac\/dkz273 (2019).","journal-title":"J. Antimicrob. Chemother."},{"key":"69228_CR49","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1093\/jac\/dkaa016","volume":"75","author":"LR Cirrincione","year":"2020","unstructured":"Cirrincione, L. R. et al. Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy. J. Antimicrob. Chemother. 75, 1242\u20131249. https:\/\/doi.org\/10.1093\/jac\/dkaa016 (2020).","journal-title":"J. Antimicrob. Chemother."},{"key":"69228_CR50","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kramer","year":"2014","unstructured":"Kramer, A., Green, J., Pollard, J. Jr. & Tugendreich, S. Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 30, 523\u2013530. https:\/\/doi.org\/10.1093\/bioinformatics\/btt703 (2014).","journal-title":"Bioinformatics"},{"key":"69228_CR51","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1172\/JCI60612","volume":"122","author":"R Dyavar Shetty","year":"2012","unstructured":"Dyavar Shetty, R. et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J. Clin. Investig. 122, 1712\u20131716. https:\/\/doi.org\/10.1172\/JCI60612 (2012).","journal-title":"J. Clin. Investig."},{"key":"69228_CR52","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ab.2006.10.020","volume":"360","author":"DS Ravi","year":"2007","unstructured":"Ravi, D. S. & Mitra, D. HIV-1 long terminal repeat promoter regulated dual reporter: potential use in screening of transcription modulators. Anal. Biochem. 360, 315\u2013317. https:\/\/doi.org\/10.1016\/j.ab.2006.10.020 (2007).","journal-title":"Anal. Biochem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69228-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69228-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69228-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T14:36:14Z","timestamp":1670337374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69228-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["69228"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-69228-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"assertion":[{"value":"20 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12565"}}